Novartis and Medicines for Malaria Venture report positive results for Phase 2b study of novel ganaplacide/lumefantrine combination in children with malaria

… Phase 2b study results for novel non-artemisinin combination to treat … . The study tested ganaplacide, a novel agent with an entirely new … , Medicines for Malaria Venture and Singapore Economic Development Board supported joint …